Industries > Pharma > Pharmaceutical Contract Manufacturing Market 2017-2027

Pharmaceutical Contract Manufacturing Market 2017-2027

Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages

PUBLISHED: 02 February 2017
PAGES: 235
PRODUCT CODE: PHA0167

Clear
WOOCS 2.2.1
SKU: PHA0167 Categories: , ,

The pharmaceutical contract manufacturing market is expected to grow at a CAGR of 6.4% in the first half of the forecast period and CAGR of 5.7% in the second half of the forecast period. The market is estimated at $88bn in 2021 and $124bn in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 235-page report you will receive 82 tables and 61 figures– all unavailable elsewhere.

The 235-page report provides clear detailed insight into the pharmaceutical contract manufacturing market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Pharmaceutical Contract Manufacturing Market 2017-2027

Report Scope
Global Pharmaceutical Contract Manufacturing Market forecasts from 2017-2027

Submarket forecasts at world level, from 2017-2027:
Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products
Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages and other dosage types
Other applications of outsourced production – other related services

Revenue forecasts from 2017-2027, for 12 countries:
– United States (US)
– EU5: Germany, France, the UK, Italy and Spain
– BRIC: Brazil, Russia, India and China
– South Korea
– Japan

• Assessment of selected leading companies that hold major market shares in the pharmaceutical contract manufacturing industry

Qualitative Analysis from a CMO Perspective 2016-2027

Qualitative Analysis from a Client Perspective 2016-2027

Visiongain’s study is intended for anyone requiring commercial analyses for the Pharmaceutical Contract Manufacturing Market. You find data, trends and predictions.

Buy our report today Pharmaceutical Contract Manufacturing Market 2017-2027: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Pharmaceutical Contract Manufacturing Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Pharmaceutical Contract Manufacturing Market 2017-2027


Latest Pharma news

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

READ

Categories

Category